Ultragenyx Pharmaceutical Inc. (RARE)
$25.68-$0.58 (-2.21%) Today
Howard Horn - OfficerHoward Horn - OfficerKarah Herdman Parschauer - OfficerHoward Horn - OfficerUltragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 6 | 19,846 | $527K |
46 Form 4 filings on record, the earliest from Oct 11, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Karah Herdman Parschauer - Officer | Open-market sale | Common Stock | 1,900 | $24.92 | $47K | |
| Howard Horn - Officer | Open-market sale | Common Stock | 4,696 | $24.92 | $117K | |
| Howard Horn - Officer | Open-market sale | Common Stock | 4,698 | $33.13 | $156K | |
| Corazon (Corsee) D. Sanders | Open-market sale | Common Stock | 2,000 | $25.05 | $50K | |
| Karah Herdman Parschauer - Officer | Open-market sale | Common Stock | 1,899 | $24.62 | $47K | |
| Howard Horn - Officer | Open-market sale | Common Stock | 4,653 | $23.77 | $111K | |
| Matthew K. Fust | Grant or award | Common Stock | 7,751 | $0.00 | - | |
| Matthew K. Fust | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
| Shehnaaz Suliman | Grant or award | Common Stock | 7,751 | $0.00 | - | |
| Shehnaaz Suliman | Open-market sale | Common Stock | 5,740 | $25.12 | $144K | |
| Shehnaaz Suliman | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
 Amrit Ray | Grant or award | Common Stock | 7,751 | $0.00 | - | |
| Amrit Ray | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
| Corazon (Corsee) D. Sanders | Grant or award | Common Stock | 7,751 | $0.00 | - | |
| Corazon (Corsee) D. Sanders | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
 Michael Narachi | Grant or award | Common Stock | 7,751 | $0.00 | - | |
| Michael Narachi | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
| Daniel G. Welch | Grant or award | Common Stock | 7,751 | $0.00 | - | |
| Daniel G. Welch | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
 Deborah Dunsire | Grant or award | Common Stock | 7,751 | $0.00 | - | |
| Deborah Dunsire | Grant or award | Stock Option (Right to Buy) | 14,058 | $0.00 | - | |
| Eric Crombez - Officer | Open-market sale | Common Stock | 344 | $24.96 | $9K | |
| Howard Horn - Officer | Open-market sale | Common Stock | 4,683 | $24.90 | $117K | |
 Theodore Alan Huizenga - Officer | Grant or award | Common Stock | 20,241 | $0.00 | - | |
| Theodore Alan Huizenga - Officer | Grant or award | Stock Option (Right to Buy) | 7,348 | $0.00 | - | |
| Emil D. Kakkis - Officer | Grant or award | Common Stock | 76,745 | $0.00 | - | |
| Emil D. Kakkis - Officer | Grant or award | Stock Option (Right to Buy) | 132,693 | $0.00 | - | |
| Dennis Karl Huang - Officer | Grant or award | Common Stock | 23,116 | $0.00 | - | |
| Dennis Karl Huang - Officer | Grant or award | Stock Option (Right to Buy) | 79,936 | $0.00 | - | |
 John Richard Pinion - Officer | Grant or award | Common Stock | 23,116 | $0.00 | - | |
| John Richard Pinion - Officer | Grant or award | Stock Option (Right to Buy) | 79,936 | $0.00 | - | |
| Karah Herdman Parschauer - Officer | Grant or award | Common Stock | 28,895 | $0.00 | - | |
| Karah Herdman Parschauer - Officer | Grant or award | Stock Option (Right to Buy) | 49,960 | $0.00 | - | |
| Erik Harris - Officer | Grant or award | Common Stock | 28,895 | $0.00 | - | |
| Erik Harris - Officer | Grant or award | Stock Option (Right to Buy) | 49,960 | $0.00 | - | |
| Eric Crombez - Officer | Grant or award | Common Stock | 34,674 | $0.00 | - | |
| Eric Crombez - Officer | Grant or award | Stock Option (Right to Buy) | 59,952 | $0.00 | - | |
| Howard Horn - Officer | Grant or award | Common Stock | 34,674 | $0.00 | - | |
| Howard Horn - Officer | Grant or award | Stock Option (Right to Buy) | 59,952 | $0.00 | - | |
| Howard Horn - Officer | Open-market sale | Common Stock | 4,683 | $20.97 | $98K | |
| Karah Herdman Parschauer - Officer | Open-market sale | Common Stock | 6,018 | $21.40 | $129K | |
| Karah Herdman Parschauer - Officer | Open-market sale | Common Stock | 3,508 | $22.67 | $80K | |
| John Richard Pinion - Officer | Grant or award | Common Stock | 11,137 | $0.00 | - | |
| John Richard Pinion - Officer | Open-market sale | Common Stock | 10,029 | $22.80 | $229K | |
| Erik Harris - Officer | Open-market sale | Common Stock | 10,539 | $22.80 | $240K | |
| Erik Harris - Officer | Grant or award | Common Stock | 11,643 | $0.00 | - | |
| Emil D. Kakkis - Officer | Grant or award | Common Stock | 71,177 | $0.00 | - | |
| Emil D. Kakkis - Officer | Open-market sale | Common Stock | 54,404 | $22.80 | $1.24M | |
| Karah Herdman Parschauer - Officer | Grant or award | Common Stock | 11,137 | $0.00 | - | |
| Karah Herdman Parschauer - Officer | Open-market sale | Common Stock | 8,135 | $22.80 | $185K | |
| Theodore Alan Huizenga - Officer | Tax withholding / forfeiture | Common Stock | 148 | $23.39 | $3K | |
| Theodore Alan Huizenga - Officer | Open-market sale | Common Stock | 1,632 | $22.80 | $37K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| HOWARD HORN | Officer | 4,696 | $117K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Ultragenyx Pharmaceutical Inc. (RARE) had 6 insider filings in the last 90 days, with the most recent on 2026-08-04. The full record for RARE runs to 46 Form 4 filings, the earliest from 2024-10-11. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of RARE were filed in the last 90 days.
6 insider sales of RARE were filed in the last 90 days, totaling $527K.
This page tracks RARE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add RARE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
